Robert E. Gagnon - 02 Sep 2025 Form 4 Insider Report for Opus Genetics, Inc. (IRD)

Role
Chief Financial Officer
Signature
/s/ Amy Rabourn, by Power of Attorney
Issuer symbol
IRD
Transactions as of
02 Sep 2025
Net transactions value
$0
Form type
4
Filing time
11 Sep 2025, 18:03:52 UTC
Previous filing
18 Jul 2025
Next filing
18 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gagnon Robert E. Chief Financial Officer C/O OPUS GENETICS, INC., 8 DAVIS DRIVE, SUITE 220, DURHAM /s/ Amy Rabourn, by Power of Attorney 11 Sep 2025 0001504983

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRD Common Stock Award $0 +200,000 $0.000000 200,000 10 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRD Employee Stock Option (right to buy) Award $0 +250,000 $0.000000 250,000 02 Sep 2025 Common Stock 250,000 $1.23 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units which vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.
F2 The option will vest with respect to 25% on September 2, 2026, with the remaining shares vesting in equal monthly installments on the last day of each full month over the next thirty-six (36) months, subject to the Reporting Person's continuing service.